25 October 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Presentation of Midkine Antibody Program Update at the Festival of Biologics Conference

Abstract accepted at leading biological therapeutics conference

 

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market , is pleased to announce that its Midkine antibody program update will be presented on 3 November 2022 at the Festival of Biologics conference in Basel, Switzerland. The ROQA1 (CAB 102) and ROQA2 (CAB101) programs have demonstrated efficacy in validated in vivo models of breast cancer and osteosarcoma resulting in a significantly reduced metastatic index (P<0.05), safety in rodent and non-human primates toxicology studies, and scalable production of CAB102.

The poster is embargoed until the presentation at the conference but will then be available at the Roquefort Therapeutics website.

The title of the presentation poster and presenter details will be published on the conference website today:

https://www.terrapinn.com/conference/festival-of-biologics/Posters.stm

 

-Ends-

Enquiries:

Roquefort Therapeutics plc
Stephen West (Chairman) / Ajan Reginald (CEO)	+44 (0)20 3918 8633
Hybridan LLP (Joint Broker) Claire Louise Noyce   Optiva Securities Limited (Joint Broker)	+44 (0)203 764 2341
Christian Dennis   Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale	+44 (0)20 3411 1881     +44 (0)20 7466 5000

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

 

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

 

Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines.  The highly complementary profile of four best-in-class medicines consists of:

· Midkine antibodies with significant in vivo efficacy and toxicology studies;

· Midkine RNA therapeutics with novel anti-cancer gene editing action;

· MK cell therapy with direct and NK-mediated anti-cancer action; and

· siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

 

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.